Yellow barberry shrubs beside a riverside path where a person walks a dog at sunrise
October 08, 2026

Berberine and GLP-1 Drugs (Ozempic, Wegovy, Zepbound): What We Know

By SciRouter Editorial Team · Last reviewed: 9 October 2026

Berberine is not a substitute for Ozempic, Wegovy or Zepbound. In 68- to 72-week trials of adults with overweight or obesity and no diabetes, weekly semaglutide or tirzepatide lowered body weight by about 15% to 21%, versus 2% to 3% on placebo[1, 2]. The largest pooled analysis of berberine trials we found reported an average 0.88 kg difference versus control[3].

Important: Don't stop or change a prescribed medication without talking to your prescriber.

GLP-1 drugs are now common. In a KFF poll of 1,350 US adults in late 2025, 18% said they had ever taken one and 12% said they were taking one now[4]. This page covers how berberine compares with these drugs and what research shows about coming off Ozempic and similar medicines. For the wider evidence on the supplement itself, start with our guide to what berberine research shows.

How we researched this. On 8 October 2026 we searched PubMed through NCBI E-utilities, read open full text in Europe PMC where available, and checked ClinicalTrials.gov, a KFF survey, FDA drug labels on DailyMed and agency pages (NIH NCCIH, LactMed and France's ANSES). We put human randomized trials and meta-analyses first and labeled animal and cell studies by species. We cite only sources we opened and checked against PubMed, Crossref or the original site; this page cites 38. We have no berberine product and no affiliate links. This page is not medical advice.

Is berberine "nature's Ozempic"?

No. We found no published human trial that compared berberine with any GLP-1 drug, and separate trials found far smaller weight effects for berberine than for semaglutide[1, 3, 5].

GLP-1 drugs are prescription medicines[6]. Semaglutide is the active ingredient in Ozempic and Wegovy, and tirzepatide is the active ingredient in Mounjaro and Zepbound[6]. On FDA labels, Ozempic is approved for adults with type 2 diabetes, while Wegovy and Zepbound are approved for weight management, together with a reduced-calorie diet and more physical activity, in adults with obesity, or with overweight plus a weight-related condition[7–9]. FDA told TODAY.com in 2025 that there are no FDA-approved drug products containing berberine[6].

The dose and the patient group matter. The best-known semaglutide weight result comes from STEP 1, which tested 2.4 mg injected once a week in adults with overweight or obesity and no diabetes[1]. That is the usual Wegovy injection maintenance dose; Ozempic, prescribed for type 2 diabetes, has a maximum of 2 mg a week[7, 8]. In the 68-week STEP 2 trial of 1,210 adults with overweight or obesity and type 2 diabetes, semaglutide 2.4 mg lowered weight by 9.6%, versus 3.4% on placebo[10].

Berberine is a compound found in plants such as goldenseal, barberry and Oregon grape[11]. In mouse fat cells and rat muscle cells grown in the lab, it switched on AMPK, an energy sensor inside cells[12]. In mice and rats, it lowered body weight[12]. In a 12-week trial in China, all 409 adults with newly diagnosed type 2 diabetes first took the antibiotic gentamicin for a week, as part of the study design[13]. HbA1c (a lab measure of average blood sugar) then fell by 0.99 percentage points with berberine 1.2 g/day, versus 0.59 with placebo[13]. The authors linked that effect to gut bacteria and bile acids[13]. For more on how it works and what human trials show, see our guide to berberine's effects in human trials.

Products sold as "GLP-1 patches" are a separate issue. FDA told TODAY.com that there are no FDA-approved GLP-1 patches[6]. Our review of berberine patches covers them.

Berberine vs Ozempic: how do the weight results compare?

In adults without diabetes, GLP-1 drug trials lowered weight by about 12 to 18 percentage points more than placebo, while pooled berberine analyses found average differences between zero and about 2 kg[1–3, 14, 15].

Study What was compared Who took part How long Weight result
STEP 1, 1,961 adults; funded by Novo Nordisk[1] Semaglutide 2.4 mg weekly vs placebo, both with a lifestyle program Overweight or obesity, no diabetes 68 weeks −14.9% vs −2.4% (−15.3 kg vs −2.6 kg)
SURMOUNT-1, 2,539 adults; funded by Eli Lilly[2] Tirzepatide 5, 10 or 15 mg weekly vs placebo Overweight or obesity, no diabetes 72 weeks −15.0%, −19.5% and −20.9% vs −3.1%
Berberine meta-analysis, 2026, 23 trials[3] Berberine vs control groups Adults; varied by trial (see the note below the table) Varied by trial −0.88 kg vs control
Berberine meta-analysis, 2020, 12 trials[14] Berberine vs control groups Not reported in the abstract (see the note below the table) Not reported in the abstract −2.07 kg vs control
Berberine meta-analysis, 2020, 10 trials[15] Berberine vs control groups Varied by trial (see the note below the table) Varied by trial −0.11 kg; not significant
Four-group trial in China, 297 adults[16] Berberine 1 g/day vs placebo Newly diagnosed high blood sugar 16 weeks −1.29 kg vs −0.42 kg; not significant
BRAVO trial in China, 337 adults[17] Berberine 1 g/day vs placebo, both with lifestyle advice Obesity and fatty liver, no diabetes 6 months −1.8 kg vs −1.9 kg; no difference. Belly (visceral) fat and liver fat, the trial's main measures, also did not differ

Read this table as a rough scale, not a contest. The studies enrolled different people for different lengths of time. Still, in kilograms, the STEP 1 difference versus placebo (12.7 kg) was more than ten times the 2026 pooled berberine estimate (0.88 kg)[1, 3]. The 297-adult trial in China had four groups, and its safety analysis counted 49 people on berberine alone and 99 on placebo[16].

Across berberine weight studies in general, NIH's National Center for Complementary and Integrative Health (NCCIH) notes that most participants had health problems, such as diabetes or fatty liver disease, that might have influenced the results, and that most of the studies were done in Asian countries[11]. NCCIH adds that a 2022 review of 18 studies found lower body weight with berberine, but many of those studies had a high risk of bias[11].

Extra weight lost versus placebo or control: berberine analyses and STEP 1 Bars drawn to scale from separate studies, not a head-to-head test. Berberine, 2026 pooled analysis of 23 trials: 0.88 kg more than control. Berberine, 2020 pooled analysis of 12 trials: 2.07 kg. Berberine, 2020 pooled analysis of 10 trials: 0.11 kg, not significant. Semaglutide 2.4 mg weekly in the 68-week STEP 1 trial of adults without diabetes: 12.7 kg more than placebo. Berberine · 23 trials pooled (2026) 0.88 kg Berberine · 12 trials pooled (2020) 2.07 kg Berberine · 10 trials pooled (2020) 0.11 kg, not significant Semaglutide 2.4 mg weekly · STEP 1, 68 weeks 12.7 kg Extra kg lost versus placebo or control. Bars drawn to scale.
Extra weight lost versus placebo or control in separate studies with different people and lengths, not a head-to-head test; the table above gives the same numbers[1, 3, 14, 15]. On a small screen, scroll the figure sideways.

You may have seen a figure of about 5 lb for berberine. One source of that figure is a 12-week pilot study in adults with obesity taking 500 mg three times a day that described no placebo group, so the change cannot be credited to berberine[18]. The authors of the 2026 meta-analysis also asked future trials to report product purity and potency and to fix problems with blinding and randomization[3].

Does berberine raise GLP-1 in people?

That has not been shown. Berberine raised GLP-1 in rats and in a lab-grown human gut cell line, but the only human trial we found that measured blood GLP-1 after repeated doses found no significant difference from placebo[16, 19, 20].

Ozempic, Wegovy and Zepbound belong to a group of prescription drugs called GLP-1 agonists; Zepbound also acts on a second hormone receptor, GIP[7–9]. The berberine idea is different: that the supplement might make the gut release more of the body's own GLP-1 (glucagon-like peptide-1), a hormone made in the gut[19]. The evidence, from animals to people:

Evidence type Who or what was studied What happened
Animal[19] Rats with chemically induced diabetes; 120 mg/kg a day for 5 weeks GLP-1 rose in blood and gut; more GLP-1-making cells
Animal and cell[20] Non-diabetic rats for 5 weeks; a human gut cell line in the lab More GLP-1 released
Human tissue[21] Gut tissue from people with obesity, exposed for 4 hours in the lab (4 samples) No change in GLP-1 gene activity
Human trial[16] Adults in China with newly diagnosed high blood sugar; 1 g/day for 16 weeks Blood GLP-1 changes did not differ from placebo
Human trial, unpublished[22] 16 healthy men in China; finished in 2023 No results posted or published

In that 16-week trial of adults in China with newly diagnosed high blood sugar, berberine 1 g/day lowered fasting glucose by 0.50 mmol/L more than placebo, but berberine alone did not significantly lower HbA1c[16]. Even so, its authors wrote that evidence that berberine regulates GLP-1 release in humans was still absent[16]. They also noted that GLP-1 acts mainly in the veins draining the gut and breaks down within about 90 seconds, so standard blood tests could miss a local rise[16].

What happens when you stop Ozempic or another GLP-1 drug?

In randomized trials, people regained much of the weight they had lost, on average, within a year of stopping semaglutide or tirzepatide[23–25]. Real-world records show smaller average regain, but they are harder to read[26].

Semaglutide has a half-life (the time the body takes to clear half of a dose) of about 1 week, so the Ozempic label says it stays in the blood for about 5 weeks after the last dose[7].

Trial Before stopping After stopping
STEP 1 extension, 327 adults, no diabetes[23] Semaglutide 2.4 mg for 68 weeks; average loss 17.3%. Drug and lifestyle program then both stopped. Regained 11.6 percentage points by week 120; net loss 5.6% from the start
STEP 4, 803 adults, no diabetes[24] Semaglutide, stepped up to 2.4 mg weekly, for 20 weeks; average loss 10.6% Next 48 weeks: +6.9% on placebo vs a further −7.9% on semaglutide; lifestyle support continued in both groups
SURMOUNT-4, 670 adults, no diabetes[25] Tirzepatide at the highest tolerated dose (10 or 15 mg weekly) for 36 weeks; average loss 20.9% Next 52 weeks: +14.0% on placebo vs a further −5.5% on tirzepatide
Weight change when people kept taking a GLP-1 drug or were switched to placebo Bars drawn to scale. STEP 4, semaglutide, the 48 weeks after week 20: people who kept taking it lost a further 7.9 percent of body weight, and people switched to placebo regained 6.9 percent. SURMOUNT-4, tirzepatide, the 52 weeks after week 36: people who kept taking it lost a further 5.5 percent, and people switched to placebo regained 14.0 percent. Both trials enrolled adults with overweight or obesity and no diabetes. ← lost weight regained → STEP 4 · semaglutide, next 48 weeks −7.9% kept taking it switched to placebo +6.9% SURMOUNT-4 · tirzepatide, next 52 weeks −5.5% kept taking it switched to placebo +14.0% % change in body weight after random assignment. Bars drawn to scale. Adults with overweight or obesity and no diabetes.
What happened in two withdrawal trials when people kept taking a GLP-1 drug or were switched to placebo; the table above gives the same numbers[24, 25]. On a small screen, scroll the figure sideways.

The STEP 1 extension authors summed up their result as regaining two-thirds of the earlier weight loss one year after stopping[23]. Those numbers come from a subset of the original trial, the analyses were exploratory, and the lifestyle program stopped at the same time as the drug[23]. Most heart and metabolic gains had moved back toward baseline by then[23].

STEP 4 suggests regain was not only about losing lifestyle support, because both groups kept that support[24]. In SURMOUNT-4, only 16.6% of people switched to placebo kept at least 80% of their earlier loss, compared with 89.5% of those who stayed on tirzepatide[25]. Even so, the placebo group was still 9.9% below its starting weight at week 88[25].

Three recent meta-analyses, which pool many studies, point the same way:

  • A 2026 BMJ analysis of 37 studies (9,341 adults with overweight or obesity) included 10 study groups (1,776 people) who stopped semaglutide or tirzepatide[27]. Their regain averaged 0.8 kg per month, or about 9.9 kg in the first year[27]. It projected a return to starting weight about 1.5 years after stopping these drugs, but its follow-up data ended at 52 weeks, so that is an estimate[27].
  • A 2025 analysis of 18 randomized trials (3,771 participants) found average regain of 5.63 kg after GLP-1 drugs were stopped in people with obesity[28]. In people with type 2 diabetes, weight rose 2.03 kg and HbA1c rose 0.65 percentage points[28].
  • A 2025 analysis of 8 randomized trials (2,372 adults with a BMI, or weight-for-height score, of 27 or more) found that regain was in proportion to the weight first lost[29]. People regained about 2.2 kg after stopping liraglutide and 9.7 kg after stopping semaglutide or tirzepatide[29].

Real-world records look different. In an Ohio and Florida health system, 7,938 adults with overweight or obesity stopped semaglutide or tirzepatide within 3 to 12 months of starting[26]. Among those who had used the drug for obesity, average weight rose 0.5% over the next year[26]. But in that year, 19.6% of all 7,938 adults restarted the same drug and 35.2% began another weight-management option[26]. So this figure does not show what happens when people stop and do nothing else, and results varied widely[26].

Why do people stop? In the KFF poll, 14% of adults who had ever used a GLP-1 drug said they no longer take it because of cost, 13% because of side effects, and 5% because their condition improved[4].

In a Copenhagen trial, adults with obesity who had lost weight on a low-calorie diet spent a year on supervised exercise, daily liraglutide 3.0 mg (a GLP-1 drug), both, or placebo[30, 31]. In the year after stopping, the liraglutide-alone group regained 6.0 kg more than the exercise group, though only 109 of 195 people came to that last visit[31].

Can berberine help after stopping Ozempic?

There is no evidence that it does. No trial we could find has tested berberine for keeping weight off after a GLP-1 drug[5].

As of 8 October 2026, we also found no published human trial of berberine taken together with a GLP-1 drug[5].

What the search did find:

  • One registered trial, listed as recruiting with no results posted, gives a multi-ingredient supplement that contains berberine, with or without semaglutide, to adults with prediabetes or type 2 diabetes[5]. It has no supplement-free group, so it cannot isolate berberine, and it does not study stopping a GLP-1 drug[5].
  • Three registered trials test supplements in people who recently stopped GLP-1 drugs, and none of them lists berberine[5].
  • A 2026 review of supplements after GLP-1 drugs said its evidence for ingredients such as berberine was extrapolated from people who were not coming off these drugs[32]. It called for more research on keeping weight off after stopping[32].

So any claim that berberine "holds" GLP-1 results after stopping does not rest on a trial[5]. A useful study would randomly assign people who are stopping a GLP-1 drug to berberine or placebo and track their weight for at least a year. We found no such study, registered or published[5].

What are the safety concerns?

The main concerns are low blood sugar, interactions with other medicines, digestive side effects, and pregnancy or breastfeeding[33–35]. We found no published trial that tested the safety of berberine taken with a GLP-1 drug[5].

Important: Berberine can interact with many medicines. People who take drugs that lower blood sugar, including GLP-1 drugs and other diabetes medicines, may be at risk of low blood sugar if they add it. Berberine is not recommended during pregnancy or breastfeeding[7, 33–35].

Low blood sugar. The Ozempic label warns that low blood sugar is more likely when Ozempic is combined with insulin or a sulfonylurea, a type of diabetes pill[7]. France's food-safety agency, ANSES, lists low blood sugar among berberine's risks and advises people with diabetes to avoid it[33]. A 2019 meta-analysis of 28 trials (2,313 people with type 2 diabetes) found that berberine combined with diabetes drugs lowered post-meal blood sugar more than the drugs alone[36]. A 2025 case report described an athletic man in his 40s taking berberine who fainted with a blood sugar of 0.9 mmol/L, which the authors linked to berberine and exercise[37]. A 2022 meta-analysis of 37 trials (3,048 people with type 2 diabetes) found no significant rise in the risk of low blood sugar with berberine, but the estimate was uncertain: the likely range ran from about 79% lower to 8% higher risk[38]. It covered berberine alone or with oral diabetes drugs, not injected drugs such as GLP-1 drugs or insulin[38].

Digestive effects and other pills. In STEP 4, digestive side effects were reported by 49.1% of people who kept taking semaglutide, versus 26.1% of those switched to placebo[24]. ANSES also lists digestive problems among berberine's risks[33]. The Ozempic label says the drug slows stomach emptying, which could affect how other pills taken while on Ozempic are absorbed[7]. In the label's drug-absorption studies, though, semaglutide did not change pill absorption to a clinically relevant degree[7].

Our guide to berberine side effects, interactions and who should not take it covers berberine's other side effects, other drug interactions, and the evidence on pregnancy and newborns.

What should you ask your prescriber?

Ask before you stop, switch or add anything. We found no published trial of berberine with or after GLP-1 drugs, so these choices belong with the clinician who knows your health[5].

Questions to bring to your prescriber:

  1. If I stop my GLP-1 medicine, how much weight regain should I expect, based on trials such as STEP 1 and SURMOUNT-4?
  2. What is our plan for keeping weight off, and how will we check my weight, blood sugar and blood pressure afterward?
  3. Do any of my medicines lower blood sugar, and would a supplement such as berberine raise my chance of low blood sugar?
  4. Are any of my medicines cleared by CYP3A4, CYP2D6 or CYP2C9, the liver enzymes berberine slowed in a human study[34]?
  5. I am pregnant, planning a pregnancy or breastfeeding. Which supplements should I avoid?
  6. If cost or side effects are why I want to stop, what other options do I have?

What is the bottom line?

In pooled trials, berberine's average effect on weight was about 2 kg at most, far smaller than with semaglutide and tirzepatide, which lowered body weight by about 12 to 18 percentage points more than placebo[1–3, 14, 15]. We found no trial testing whether berberine helps after stopping a GLP-1 drug[5].

For what berberine does and does not do in human trials, read our complete guide to berberine. For safety detail, see berberine side effects and interactions. If you take metformin, see berberine vs metformin trial results.

Ozempic and Wegovy are registered trademarks of Novo Nordisk, and Zepbound is a registered trademark of Eli Lilly[7–9]. SciRouter is not affiliated with either company.

Get our plain-English longevity research digest

Short, sourced summaries of new longevity research, written in plain English. No product pitches. Unsubscribe anytime.

Frequently asked questions

Is berberine as effective as Ozempic?

We found no published trial that compared them directly, but separate trials point to a large gap. In the 68-week STEP 1 trial of adults with overweight or obesity and no diabetes, semaglutide 2.4 mg weekly (the usual Wegovy dose) lowered weight by 14.9%, versus 2.4% on placebo. A 2026 meta-analysis of 23 berberine trials found an average difference of 0.88 kg versus control. Those numbers come from different people and study lengths[1, 3, 5, 8].

Has anyone actually lost weight with berberine?

Pooled berberine trials show at most a small average difference, and the largest recent trial found none. A 2026 meta-analysis of 23 randomized trials found 0.88 kg more weight loss with berberine than in control groups. In a 6-month trial of 337 adults with obesity and fatty liver, people taking berberine 1 g/day lost 1.8 kg and people on placebo lost 1.9 kg. Belly fat and liver fat also did not differ[3, 17].

Can you take berberine with Ozempic?

We found no published trial of berberine taken with Ozempic, so its safety alongside it is unknown. As of October 2026, the only registered trial we found that pairs a berberine-containing product with semaglutide was listed as recruiting, with no results posted. Berberine slowed several drug-clearing liver enzymes in healthy men, and people on glucose-lowering drugs may risk low blood sugar if they add it. Ask your prescriber before adding any supplement[5, 33, 34].

Has anyone gone off Ozempic and kept weight off?

A minority did in trials, but most regained much of the weight. In the STEP 1 extension, adults who lost 17.3% on semaglutide 2.4 mg (the usual Wegovy dose) were 5.6% below their starting weight one year after stopping. In SURMOUNT-4, 16.6% of people switched from tirzepatide to placebo kept at least 80% of their earlier loss. Real-world records vary more, partly because many people restart or try other options[8, 23, 25, 26].

Can you wean off Ozempic?

That is a decision to make with your prescriber, not with a supplement. This page does not review tapering studies, so it gives no tapering plan. Withdrawal trials such as STEP 4 and SURMOUNT-4 switched people to placebo and found large regain over the following 48 to 52 weeks. Don't stop or change a prescribed medication without talking to your prescriber[24, 25].

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024
  3. Elahi Vahed I, Shahir-Roudi E, Nojumi S, et al. The effect of berberine on obesity indices: a systematic review and meta-analysis. Int J Obes (Lond). 2026. PMID: 41310257
  4. KFF. KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use. 2025.
  5. SciRouter research log, 8 October 2026: searches of PubMed, Europe PMC and ClinicalTrials.gov for trials of berberine taken with or after GLP-1 drugs. The link opens one of the ClinicalTrials.gov searches: ClinicalTrials.gov search results for "berberine semaglutide".
  6. Pawlowski A. Do 'GLP-1 Patches' Work for Weight Loss? Doctors Warn About Trend. TODAY.com. 2025.
  7. U.S. National Library of Medicine, DailyMed. OZEMPIC (semaglutide) injection, solution: prescribing information. Novo Nordisk. Accessed 8 October 2026.
  8. U.S. National Library of Medicine, DailyMed. WEGOVY (semaglutide) injection, solution; WEGOVY (semaglutide) tablet: prescribing information. Novo Nordisk. Accessed 8 October 2026.
  9. U.S. National Library of Medicine, DailyMed. ZEPBOUND (tirzepatide) injection, solution; ZEPBOUND KwikPen: prescribing information. Eli Lilly and Company. Accessed 8 October 2026.
  10. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. PMID: 33667417
  11. National Center for Complementary and Integrative Health. Berberine and Weight Loss: What You Need To Know. 2023.
  12. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006. PMID: 16873688
  13. Zhang Y, Gu Y, Ren H, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020. PMID: 33024120
  14. Asbaghi O, Ghanbari N, Shekari M, et al. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2020. PMID: 32690176
  15. Xiong P, Niu L, Talaei S, et al. The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials. Complement Ther Clin Pract. 2020. PMID: 32379652
  16. Ming J, Yu X, Xu X, et al. Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study. Genome Med. 2021. PMID: 34365978
  17. Lei L, Wang B, Zhao L, et al. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. JAMA Netw Open. 2026. PMID: 41543854
  18. Hu Y, Ehli EA, Kittelsrud J, et al. Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine. 2012. PMID: 22739410
  19. Lu SS, Yu YL, Zhu HJ, et al. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J Endocrinol. 2009. PMID: 18996945
  20. Yu Y, Liu L, Wang X, et al. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol. 2010. PMID: 19945441
  21. Wang Q, Farhadipour M, Thijs T, et al. Bitter-tasting drugs tune GDF15 and GLP-1 expression via bitter taste or motilin receptors in the intestine of patients with obesity. Mol Metab. 2024. PMID: 39111389
  22. ClinicalTrials.gov. The Effect of Berberine on the Secretion of Incretin in Normal Man (NCT05947370). Registry record, accessed 8 October 2026.
  23. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022. PMID: 35441470
  24. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID: 33755728
  25. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870
  26. Gasoyan H, Schulte R, Boyer CB, et al. Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide. Diabetes Obes Metab. 2026. PMID: 41816857
  27. West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026. PMID: 41500720
  28. Tzang CC, Wu PH, Luo CA, et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine. 2025. PMID: 41399474
  29. Berg S, Stickle H, Rose SJ, et al. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obes Rev. 2025. PMID: 40186344
  30. Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021. PMID: 33951361
  31. Jensen SBK, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine. 2024. PMID: 38544798
  32. Johnson BV. Considerations for Dietary Supplements after GLP-1RA Treatment: A Narrative Review. J Nutr. 2026. PMID: 42398916
  33. ANSES. Use of berberine-containing plants in food supplements. 2019.
  34. Guo Y, Chen Y, Tan ZR, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012. PMID: 21870106
  35. Drugs and Lactation Database (LactMed). Goldenseal. National Institute of Child Health and Human Development. 2006 (revised 2025). PMID: 30000926
  36. Liang Y, Xu X, Yin M, et al. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocr J. 2019. PMID: 30393248
  37. Henshall A, Ambrogetti R, Pomeroy R, et al. Berberine-induced hypoglycaemia and electrocardiogram interpretation in athletes. BMJ Case Rep. 2025. PMID: 40903097
  38. Xie W, Su F, Wang G, et al. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Front Pharmacol. 2022. PMID: 36467075

This content is for education only and is not medical advice. Talk to your healthcare provider before starting any supplement, especially if you are pregnant, nursing, take medication, or have a medical condition.

more Blog posts

View all